First patient dosed in GE HealthCare’s Phase II/III LUMINA clinical trial
Mangaciclanol’s Phase I trial showed it was well tolerated, with no serious adverse events or clinically significant findings.
Analysis
View MoreTracking carbon, tracing change
To track and verify embodied emissions through every stage of the supply chain, leading OEMs are piloting blockchain-anchored digital product passports (DPPs). Ellie Philpotts talks to Chris Taylor, sustainability lead...
Go with the flow
Harnessing automation
How smart can it be?
Killer nanopatterns